Tilray narrows loss to $56 million on record cannabis sales

Tickets for MJBizCon 2023 in Las Vegas are on sale now! Dare to grow and discover the business solutions to elevate your cultivation operation. Buy your ticket.

Canadian cannabis producer Tilray Brands narrowed its loss to $56 million ($77 million Canadian dollars) in the first quarter on record sales of $177 million, the company said in its financial results for its first quarter of fiscal year 2024.

The revenue is 15% higher than the same period last year, boosted by cannabis sales, as the New York- and Leamington, Ontario-based company said its recreational marijuana market share improved to an industry-leading 13.4%.

Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), a measure of profitability, was $11.4 million in the first quarter ended Aug. 31.

That’s compared with $13.5 million in the same quarter last year.

Tilray reiterated its adjusted EBITDA target of $68 million-$78 million for the fiscal year ending May 31, 2024.

The company said it still expects to generate positive adjusted free cash flow this year – a critical milestone in the cannabis industry amid tight capital markets.

Tilray’s sales improved in the quarter in almost every segment.

Its cannabis business experienced a revenue increase to $70.3 million, 20% better than the same period last year.

Other segment sales were:

  • $69.2 million for its distribution business, up 11%.
  • $24.2 million for its beverage alcohol business, 17% higher than last year’s first quarter.

Revenue for Tilray’s wellness business declined to $13.5 million in the quarter, 1% less than the previous year.

Tilray’s biggest business segments were cannabis and beverage alcohol, which represented 30% of sales, respectively.

Gross cannabis revenue by market channel was:

  • $6.1 million in the June-August quarter, down slightly from $6.5 million for the same period last year.
  • $71.2 million from Canadian adult-use cannabis, up 22% over 2022.
  • $5.3 million from wholesale cannabis, up from $392,000 last year.

Revenue from international cannabis jumped 37% over last year to $14.3 million for the three months ended Aug. 31.

Cash and cash equivalents as of the end of August were $177.5 million.

In the quarter, Tilray closed on three separate transactions:

Meanwhile, the acquisition of eight beer and beverage brands from Anheuser-Busch for $85 million was completed this week.

Tilray’s shares trade as TLRY on the Nasdaq and Toronto Stock Exchange.

MediPharm’s shares trade as LABS on the TSX.